A big congratulations to the Convatec team on the regulatory approval of ConvaNiox – a major milestone for nitric oxide-based wound care.
Advancing NO Innovation: ConvaNiox Approved
read more
News
30 Technology Enrolls First Patient in Pioneering NOPA Trial for New Inhaled Antimicrobial RESP303
30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.
30 Technology announces interim results from Phase 2 tuberculosis trial
30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).
30 Technology- EMA Approval to launch a Phase 1/2a trial in patients with Non-Cystic Fibrosis Bronchiectasis
30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations
30 Technology completes final patient dosing in its TB study in South Africa
30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa.
30 Technology Holds Inaugural Scientific Advisory Board Meeting
We are delighted to announce the first meeting of 30 Technology’s newly formed Scientific Advisory Board (SAB) held in our offices in Central London.
30 Technology launches a critical clinical trial in patients with newly diagnosed tuberculosis
We are delighted to announce that our latest clinical trial ‘RESP30X-EBA’ is active and recruiting at the TASK Clinical Research Centre, South Africa.
30 Technology expands its clinical team
30 Technology has been actively engaged in expanding its clinical team to drive its lead respiratory assets through multiple ongoing early phase clinical trials.
30 Technology receives regulatory approval for TASK tuberculosis Study in South Africa
30 Technology is delighted to report that this month we received full regulatory approval to start our Phase 2 trial in adults with newly diagnosed pulmonary tuberculosis (TB).
30 Technology Expands Its Scientific Team And Opens New Innovation Hub At Scale Space, Imperial College London
30 Technology is delighted to announce the opening of its new Innovation Centre in Scale Space – a part of Imperial College London’s White City campus located in the heart of West London.